REG - Trellus Health PLC - Result of AGM

Trellus HealthAnnouncement

22/06/2023 13:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230622:nRSV6331Da&default-theme=true

RNS Number : 6331D  Trellus Health PLC  22 June 2023

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Result of AGM

 

LONDON, U.K. AND NEW YORK, U.S. (22 June 2023). Trellus Health plc (AIM:
TRLS), which is commercializing a scientifically validated, personalized
resilience-driven self-management solution for chronic health conditions at
their intersection with mental health, announces that at the Annual General
Meeting ("AGM") held earlier today, all resolutions were duly passed.

 

The voting results of the AGM were as follows:

 

             In Favour            Against         Withheld
 Resolution  Votes       %        Votes    %      Votes
 1           43,559,167  100.00%  0        0.00%  1,171
 2           43,391,049  99.95%   21,961   0.05%  147,328
 3           43,401,966  99.97%   11,044   0.03%  147,328
 4           43,110,425  98.97%   448,742  1.03%  1,171
 5           43,108,985  98.97%   450,182  1.03%  1,171

 

For further information please contact:

 

 Trellus Health plc                                                            https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, CEO and Co-Founder                                        Via Walbrook PR
 Dr. Daniel Mahony, Chairman
 Steve Young, CFO

 Singer Capital Markets (Nominated Adviser and Broker)                         Tel: +44 (0)20 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR                                  Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                                              (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen / Phillip Marriage  Mob: +44 (0)7980 541 893 / (0)7748 651 727 / (0)7867 984 082

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is the first resilience based digital health
company focused on the intersection of chronic illness and mental health.
Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and team to deliver a whole-person technology-enhanced
experience that results in relieving disease burden, building self-management
skills and promoting positive health behaviours that improves outcomes and
enables thriving in the face of a chronic condition. Through its
TrellusElevate™ connected health platform and companion App, the company
addresses both physical and behavioural health together, in context, to
improve outcomes and reduce healthcare costs across the healthcare ecosystem.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both with over 50 years of combined clinical and
research experience in IBD, IBS and psychogastroenterology, respectively.

 

The Company was initially focused on inflammatory bowel disease ("IBD"), which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis but has now added Irritable Bowel Syndrome ("IBS"). Given the common
emotional and mental health struggles often experienced by individuals
suffering from a variety of chronic conditions, Trellus Health considers its
approach to have potential utility and demand across many conditions.

 

The TrellusElevate™ platform is the Company's proprietary connected health
platform that incorporates the GRITT™ methodology and learnings on
resilience from clinical research and practice conducted at the Mount Sinai
IBD Center for more than five years. This proprietary, resilience-driven
methodology has been scientifically validated to demonstrate meaningful
improvements in patient outcomes, 71% reduction in Emergency Department
(A&E) visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for significant cost
savings for healthcare payers. Patients with IBD managed with the proprietary
resilience methodology also experienced a 49% reduction in required opioid use
and a 73% reduction in corticosteroid use 12 months following starting the
program which is a major indicator of improved health outcomes(1).

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

 

(1) Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258) )

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGUUOUROVUNUAR